News & Updates
Filter by Specialty:
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
Maintenance lebrikizumab monotherapy appears to improve outcomes in patients with moderate-to-severe atopic dermatitis (AD), according to results of the phase III ADvocate1 and ADvocate2 trials.
Lebrikizumab efficacy in atopic dermatitis maintained at 1 year
12 Oct 2022
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
Long-term treatment with carvedilol lowers the risk of decompensation of cirrhosis and improves survival in compensated patients with clinically significant portal hypertension (CSPH), reports a study.
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
12 Oct 2022
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
In the second interim overall survival (OS) analysis of the phase III TROPiCS-02 study, sacituzumab govitecan (SG) – a first-in-class Trop-2*-directed antibody-drug conjugate approved for triple-negative metastatic breast cancer (mBC) with ≥2 prior therapies (≥1 in the metastatic setting) – conferred an OS benefit for pretreated HR+/HER2– mBC, compared with treatment of physician’s choice (TPC**).
Sacituzumab govitecan confers OS benefit for HR+/HER2– metastatic breast cancer
12 Oct 2022
Stress spikes BP levels in hypertensive adults
In adults with hypertension, highly stressful situations or emotions lead to an increase in blood pressure (BP), according to a recent study. Using a wearable BP monitoring device can help detect these BP spikes.
Stress spikes BP levels in hypertensive adults
12 Oct 2022
Safinamide for Parkinson’s: Dyskinesia up short term, motor symptoms down long term
A post-hoc analysis of a phase III trial of long-term safinamide for Parkinson’s disease (PD) finds a significant early increase in pre-existing dyskinesia as well as improved motor symptoms in patients with or without pre-existing dyskinesia at 1 year.